Heidi Crayton, MD, and Maria Lopes, MD, discuss the impact of multiple sclerosis on patients, families, and caregivers, differentiate relapsing forms (relapsing-remitting and primary progressive) from ...
—Mayo Clinic investigators assessed the effect of reproductive history—including number of pregnancies and age at menopause--on the development of progressive MS in women. Share on Facebook. Opens in ...
Mitoxantrone hydrochloride was the first FDA-approved medication for both secondary-progressive multiple sclerosis (MS) and progressive-relapsing MS. It’s also used to treat relapsing-remitting MS ...
MS research suggests the disease may be divided into two biological subtypes that differ in how early and aggressively nerve ...
– Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End of 2026 – – Additional Data from Phase 2 CALLIPER Trial in ...
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application for tolebrutinib for the treatment of non-relapsing secondary progressive multiple sclerosis (nrSPMS).
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today highlighted its 2025 ...
Basel, 16 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq) ...
A long-term study has identified a potential biomarker that could help detect which patients are progressing toward more severe forms of multiple sclerosis.
SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's ...
A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback